spacer
home > pmps > autumn 2008 > universal clarity
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Universal Clarity

People with a visual impairment often experience problems in differentiating packets, with the increased standardisation of packaging sizes and shapes. They can also have problems with reading the instructions since they are often printed in a small typeface with poor visual quality. In order to alleviate these problems, the European Commission has issued a directive requiring suppliers of pharmaceutical products to incorporate braille labels and produce information leaflets in alternative formats. However, the associated standard has yet to be published, which leaves uncertainty about the detailed implementation of the directive.

Packaging poses significant problems for many older people. This is often due to an inability to read the label, understand its meaning or open the package without damaging the contents. Failure to take medicine correctly has been estimated to cost the US economy $100 billion per year (1).

THE VISUALLY IMPAIRED POPULATION

About 1.5 per cent of the population could be officially registered as ‘blind’ or ‘partially sighted’. Of these, around 0.4 per cent have to rely on non-visual methods to access information (2)...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr John Gill, OBE DSc FIET, is Chief Scientist at RNIB in the UK. He has worked for over 35 years in the area of scientific and technological research for people with disabilities. His research has included the design of fonts, public access terminals, tactile communication, orientation systems, automated production of braille and large print, smart card and biometric systems, and accessibility of information and communication technology systems and services. He has visited over 40 countries and written over 200 publications.
spacer
Dr John Gill
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

The CPhI Annual Report

The global pharmaceutical landscape is evolving at an extraordinary pace as manufacturing capabilities, drug development technologies, and regulation advances creating new ways of innovating drugs and better serving patients.
More info >>

White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement